Compare ADMA Biologics Inc (ADMA) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Vanguard Total Stock Market Index Fund ETF trades at $367.74. The key difference: Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | VTI | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | — |
52-Week High | $20.38 | $374.36 |
52-Week Low | $7.60 | $305.58 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
VTI trades at $371.67, up 0.79% today, with a bullish technical outlook supported by moving averages. The ETF offers broad U.S. equity exposure across 3,400+ stocks with a minimal 0.03% expense ratio. Recent news highlights its inclusion in new Trump Accounts and comparisons with competing total market ETFs, reinforcing its popularity for long-term wealth building.
VTI presents a low-cost core holding for diversified U.S. stock exposure, though its neutral oscillators and elevated short-term RSI suggest near-term consolidation risks. Market volatility and economic shifts remain key headwinds, but analyst sentiment favors its long-term growth potential amid accelerating small-cap earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
